TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

被引：34
|
作者：
Yi, Ming [1 ,2 ]
Li, Tianye [3 ]
Niu, Mengke [1 ]
Wu, Yuze [1 ]
Zhao, Zhenyu [4 ]
Wu, Kongming [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Breast Surg, Hangzhou, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Gynecol, Hangzhou, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Urol, Tongji Med Coll,Dept Urol, Wuhan, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金：
中国博士后科学基金; 中国国家自然科学基金;
关键词：
cancer biotherapy; cancer immunotherapy; tumor microenvironment; TGF-beta; PD-1; PD-L1; bispecific antibody; NONSMALL CELL LUNG; SMALL-MOLECULE INHIBITOR; SODIUM LY573636 SODIUM; MONOCLONAL-ANTIBODY; BELAGENPUMATUCEL-L; TASISULAM SODIUM; PD-1; BLOCKADE; BREAST-CANCER; LY2157299; MONOHYDRATE; ANTITUMOR-ACTIVITY;
D O I：
10.3389/fimmu.2022.1061394
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Transforming growth factor-beta (TGF-beta) signaling regulates multiple physiological processes, such as cell proliferation, differentiation, immune homeostasis, and wound healing. Besides, TGF-beta plays a vital role in diseases, including cancer. Accumulating evidence indicates that TGF-beta controls the composition and behavior of immune components in the tumor microenvironment (TME). Advanced cancers leverage TGF-beta to reshape the TME and escape immune surveillance. TGF-beta-mediated immune evasion is an unfavorable factor for cancer immunotherapy, especially immune checkpoint inhibitors (ICI). Numerous preclinical and clinical studies have demonstrated that hyperactive TGF-beta signaling is closely associated with ICI resistance. It has been validated that TGF-beta blockade synergizes with ICI and overcomes treatment resistance. TGF-beta-targeted therapies, including trap and bispecific antibodies, have shown immense potential for cancer immunotherapy. In this review, we summarized the predictive value of TGF-beta signaling and the prospects of TGF-beta-targeted therapies for cancer immunotherapy.
引用
收藏
页数：12
相关论文
共 50 条
  • [1] Pneumonitis with anti-PD-1/PD-L1 therapy
    Naidoo, J.
    Cunningham, J.
    Woo, K. M.
    Hellmann, M. D.
    Postow, M. A.
    Drilon, A. E.
    Chaft, J. E.
    Lesokhin, A. M.
    Segal, N. H.
    Callahan, M. K.
    Rudin, C. M.
    Iyriboz, T.
    Wolchok, J. D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S103 - S103
  • [2] Pneumonitis From Anti-PD-1/PD-L1 Therapy
    Balaji, Aanika
    Verde, Franco
    Suresh, Karthik
    Naidoo, Jarushka
    [J]. ONCOLOGY-NEW YORK, 2017, 31 (10): : 739 - +
  • [3] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Niu, Mengke
    Yi, Ming
    Li, Ning
    Luo, Suxia
    Wu, Kongming
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [4] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Mengke Niu
    Ming Yi
    Ning Li
    Suxia Luo
    Kongming Wu
    [J]. Experimental Hematology & Oncology, 10
  • [5] Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
    Mishra, Surbhi
    Amatya, Sajeen Bahadur
    Salmi, Sonja
    Koivukangas, Vesa
    Karihtala, Peeter
    Reunanen, Justus
    [J]. CANCERS, 2022, 14 (20)
  • [6] Impact of PD-L1 feedback modulation on the sensitivity of anti-PD-1/PD-L1
    Zhu, Jian
    Zhu, Rebecca L.
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [7] Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
    de Jong, Florus C.
    Rutten, Vera C.
    Zuiverloon, Tahlita C. M.
    Theodorescu, Dan
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 15
  • [8] Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy
    Kirienko, Margarita
    Sollini, Martina
    Chiti, Arturo
    [J]. CLINICAL AND TRANSLATIONAL IMAGING, 2018, 6 (06) : 417 - 427
  • [9] Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy
    Margarita Kirienko
    Martina Sollini
    Arturo Chiti
    [J]. Clinical and Translational Imaging, 2018, 6 : 417 - 427
  • [10] Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
    Sundararajan, Srinath
    Vogelzang, Nicholas J.
    [J]. FUTURE ONCOLOGY, 2015, 11 (16) : 2299 - 2306
12345